N-pyridin-3-ylmethoxy-phthalimide | 30777-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: N-pyridin-3-ylmethoxy-phthalimide
• 英文别名: 2-(3-pyridinylmethoxy)-1H-isoindole-1,3(2H)-dione；N-phthaloyl-O-pyridin-3-ylmethyl-hydroxylamine；N-(3-Pyridylmethoxy)-phthalimid；2-(Pyridin-3-ylmethoxy)isoindoline-1,3-dione；2-(pyridin-3-ylmethoxy)isoindole-1,3-dione
• CAS: 30777-95-8
• 化学式: C₁₄H₁₀N₂O₃
• 分子量: 254.245
• InChiKey: PLNOXXFMIVONEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  59.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 包装等级：
  III
• 危险类别：
  9
• 危险性防范说明：
  P501,P273,P260,P270,P264,P280,P391,P314,P337+P313,P305+P351+P338,P301+P312+P330
• 危险品运输编号：
  3077
• 危险性描述：
  H302,H319,H372,H410
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  N-pyridin-3-ylmethoxy-phthalimide 在 吡啶 、 甲基肼 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 ((2R,3S)-3-acetoxy-6-((10R,13S,17S)-10,13-dimethyl-17-((E)-1-(pyridin-3-ylmethoxyimino)ethyl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yloxy)-3,6-dihydro-2H-pyran-2-yl)methyl acetate
  参考文献：
  名称：

  Glucal-conjugated sterols as novel vascular leakage blocker: Structure–activity relationship focusing on the C17-side chain

  摘要：

  A series of glucal-conjugated sterols as novel vascular leakage blocker were identified through design, synthesis and biologically evaluation. In addition, the structure-activity relationship (SAR) of the glucal-conjugated sterols focusing on the C-17-side chain was also established. The sterol analogs linked with the rigid C-17-side chain side chains exhibited potent cell survival activities. In particular, analog 211, which possesses a cyclopentyl oxime moiety, was shown to have excellent pharmacological effects on retinal vascular leakage in a diabetic mouse model. (C) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.01.027
• 作为产物：
  描述：

  3-吡啶甲醛 在 lithium aluminium tetrahydride 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 为溶剂， 反应 18.5h， 生成 N-pyridin-3-ylmethoxy-phthalimide
  参考文献：
  名称：

  Identification of Human Alanine–Glyoxylate Aminotransferase Ligands as Pharmacological Chaperones for Variants Associated with Primary Hyperoxaluria Type 1

  摘要：

  DOI：

  10.1021/acs.jmedchem.2c00142

文献信息

• [EN] 2-CYANOPYRROLIDINE DERIVATIVES AND THEIR USE AS DPP-IV INHIBITORS<br/>[FR] DERIVES 2-CYANOPYRROLIDINE ET LEUR UTILISATION COMME INHIBITEURS DE LA DPP-IV
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2004099185A1

  公开（公告）日：2004-11-18

  A compound of the formula (I) or a pharmaceutically acceptable salt thereof: [wherein X is CFH, or CF?2#191, R1 is the moiety represented by the formula: [wherein R2 is (lower)alkyl, R3 is phenyl-(lower)alkyl, and the like.], and the like.] Compounds of formula (I) inhibit DPP-IV activity. They are therefore useful in the treatment of conditions mediated by DPP-IV, such as NIDDM.

  化合物的结构式（I）或其药学上可接受的盐：[其中X为CFH，或CF?2＃191，R1为由以下结构式表示的基团：[其中R2为（较低）烷基，R3为苯基-（较低）烷基等。]，等等。] 公式（I）的化合物抑制DPP-IV活性。因此，它们在治疗由DPP-IV介导的疾病，如NIDDM中是有用的。
• [EN] OXIM DERIVATIVES AS HSP90 INHIBITORS<br/>[FR] DÉRIVÉS D'OXIME EN TANT QU'INHIBITEURS DE HSP90
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009097578A1

  公开（公告）日：2009-08-06

  The invention relates to HSP90 inhibiting compounds consisting of the formula: (I) wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及具有式(I)结构的HSP90抑制化合物，其中变量如本文所定义。本发明还涉及包含此类化合物的药物组合物、套件和制造品；制备这些化合物的方法和中间体；以及使用这些化合物的方法。
• [EN] 6-11 BICYCLIC KETOLIDE DERIVATIVES<br/>[FR] DERIVES DE CETOLIDE 6-11 BICYCLIQUES
  申请人：ENANTA PHARM INC

  公开号：WO2003097659A1

  公开（公告）日：2003-11-27

  The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了以下式(I)的化合物，或其药学上可接受的盐、酯或前药：具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗生素治疗的受试者使用。该发明还涉及通过给受试者使用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• [EN] 6-11 BICYCLIC KETOLIDE DERIVATIVES<br/>[FR] DERIVES KETOLIDES BICYCLIQUES 6-11
  申请人：ENANTA PHARM INC

  公开号：WO2005061525A1

  公开（公告）日：2005-07-07

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物，或其药学上可接受的盐、酯或前药：(I)，这些化合物具有抗菌性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗生素治疗的受试者进行治疗。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。
• [EN] 6-11 BICYCLIC KETOLIDE DRIVATIVES<br/>[FR] DERIVES DE KETOLIDE 6-11 BICYCLIQUES
  申请人：ENANTA PHARM INC

  公开号：WO2005061526A1

  公开（公告）日：2005-07-07

  The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: Formule (I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

  本发明公开了具有以下结构的化合物I，或其药学上可接受的盐、酯或前药：Formule (I)，其具有抗菌性能。本发明还涉及包括上述化合物的药物组合物，用于给需要抗生素治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。该发明还包括制备本发明化合物的方法。